Wednesday, August 25, 2021
Smart Meter, the leader in cellular-connected remote patient monitoring (RPM) devices, data and services, today announced the availability of its iGlucose monitor for managing gestational diabetes. iGlucose provides those with gestational diabetes an easy and reliable way to test, monitor and manage their blood glucose levels, ensuring that all care providers have immediate access to testing results.
According to the CDC, every year, 2% to 10% of, or 700,000, pregnancies in the United States are affected by gestational diabetes. Usually tested around week 24 of pregnancy, gestational diabetes can be effectively controlled if blood glucose is monitored and care is overseen by a provider.
"We've seen great success with our iGlucose monitors in other markets, such as long-term care (LTC), and we're thrilled to now offer our solution to support women with gestational diabetes," said Casey Pittock, CEO, Smart Meter. "Pregnancy can be a stressful time. iGlucose can help provide peace of mind that patients are getting the best care and support possible."
Key Benefits of iGlucose in Gestational Diabetes include:
Immediate transmission of BG data through cellular connectivity with AutoShare™
Improved patient experience through a cellular-enabled device
Remote patient monitoring (RPM) reporting capabilities through professional dashboards
iGlucose's cellular connectivity with AutoShare™ immediately transmits blood glucose data upon testing, delivering critical high and low readings in real-time to providers. More convenient and easier for patients, results can be viewed immediately by care providers who can react in real-time to adjust diet or medicines, potentially reducing costs and trips to the hospital.